ProCE Banner Activity

BCMA-Targeting Agents in Relapsed/Refractory Multiple Myeloma: Current Approved Indications and General Management of Toxicities

PDF

Download this resource for useful point-of-care information including current approvals, clinical trial data, and AE identification and management with BCMA-targeting agents.

Released: June 23, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb

Regeneron Pharmaceuticals, Inc